Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation: A Post Hoc Analysis of the MATTERHORN Trial
- PMID: 39475706
- DOI: 10.1161/CIRCULATIONAHA.124.072648
Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation: A Post Hoc Analysis of the MATTERHORN Trial
Keywords: atrial functional mitral regurgitation; mitral regurgitation; randomized controlled trial; surgery; transcatheter edge-to-edge repair.
Conflict of interest statement
S.B. reports an unrestricted research grant for the MATTERHORN trial from Abbott Vascular; an unrestricted research grant to perform a study in patients with heart failure receiving a myeloperoxidase inhibitor; and consultant honoraria from Edwards Lifesciences. R.P. reports the following: speaker engagement with Abbott Vascular and consultant for Edwards Lifesciences. M.K. reports a grant/contract from Abbott Vascular and Edwards Lifesciences. P.B. reports a consultant agreement for proctoring from Abbott Vascular. E.L. reports research funding from Abbott Vascular and Edwards Lifesciences; a grant/contract from Abbott Vascular and Edwards Lifesciences; speaker honoraria from Abbott, Abiomed, AstraZeneca, Bayer, Edwards Lifesciences, and Novartis; travel support from Abbott, Abiomed, AstraZeneca, Bayer, Cardiovalve, Edwards Lifesciences, Novartis, and New Valve Technology; and data safety monitoring board in New Valve Technology, Novartis, and Cardiovalve. J.G. reports the following: lecture fees from Abbott Vascular and Edwards Lifesciences, consultant as advisory board member in Berlin Heart, as selection committee in Fine Heart, and as advisory board member in Medtronic. M.K. reports grants/contracts from Abbott Vascular, Abiomed, Amgen, Braun Medical, Boston Scientific, Daiichi Sankzo Europe, Deutsche Forschungsgesellschaft, Edwards Lifesciences, Mars Scientific Advisory Council, Medtronic, Microvision, and Philips. J.H. reports consultant and travel fees from Edwards Lifesciences. A.S. reports speaker engagement with Abbott Vascular. H.I. is a consultant for Abbott Vascular. P.L. reports the following: consultant for Abbott Vascular, Boehringer Ingelheim, Edwards Lifesciences, Innoventric, Medtronic, ReCor; grant/contract from Boehringer Ingelheim and ReCor; stock option from Innoventric. R.S.B. reports the following: echocardiography core laboratory contract with University of Göttingen (RESHAPE-HF II trial) and echo corelab contract with University of Cologne (MATTERHORN trial); consulting fees from Abbott Vascular, Edwards Lifesciences, Jenscare, and Medtronic; honoraria from Abbott Vascular, Edwards Lifesciences, Jenavalve, Jenscare, Medtronic, Philips, and Siemens; data safety monitoring board member for Medtronic; and committee member of Heart Valve Society and European Union Structural Heart Disease Coalition. T.N. received grants/contracts from Abbott Vascular, Edwards Lifesciences, and Medtronic. H.R. reports lecture fees from Edwards Lifesciences. W.R. reports a consultant agreement from Abbott Vascular. P.C.S. reports data and safety monitoring for Abbott Vascular, AstraZeneca, and Bayer; grants/contracts from Abiomed, Boehringer Ingelheim, Bundeministerium für Bildung und Forschung, Deutsche Herzstiftung, Edwards Lifesciences, and Else-Kröner-Fresenius-Stiftung; and speaker engagement with Abiomed, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifesciences, Medtronic, and Pharmacosmos Therapeutics. W.M. reports funding from the Department of Cardiology, University of Cologne, as payment to the Institute of Medical Statistics and Computational Biology, University of Cologne. M.H. reports employment with the University of Cologne. V.R. reports a grant/contract from Abbott Vascular and Edwards Lifesciences. C.I. reports travel expenses and consultant honoraria from Abbott Vascular and Edwards Lifesciences. The other authors report no conflicts.
Publication types
LinkOut - more resources
Full Text Sources